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nant-methionyl interferon consensus; r-huG-CSF = recombinant-methionyl human granulocyte colony-stimulating factor; TI = technosphere–insulin
formulation; TSH = thyroid-stimulating hormone.
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Introduction
The techniques of recombinant DNA technology have
been well refined during the past 20 years such that it is
now possible to produce, under good manufacturing prac-
tice conditions, commercial quantities of therapeutic pep-
tides and proteins. It is expected that, during the next
decade, an even greater number of molecular targets will
be identified for treatment of various diseases. These are
exciting developments, not only for scientists, but also for
patients, because such biotherapeutic agents are very
specific in their actions, and thus will greatly improve the
quality of life for the majority of patients.
Hundreds of bioengineered proteins and peptides are
either already on the market or are undergoing clinical
investigation; these include growth factors, hormones,
monoclonal antibodies, cytokines and anti-infective
agents, among others. However, these compounds have
unusual characteristics that present considerable chal-
lenges to formulation scientists. The combination of their
large molecular size, hydrophilicity and lability (both chemi-
cal and enzymatic) virtually exclude their formulation in tra-
ditional dosage forms such as tablets and capsules.
Consequently, most proteins and peptides currently on
the market are injectable. This route of drug administration
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is generally not preferable to patients, in particular
because the indication for the use of these agents is
usually treatment of a chronic condition. This leads to low
patient compliance and an increase in the cost of therapy.
Formulation scientists have generally approached this
challenge from two directions (Fig. 1): controlled release
injections or drug administration via alternative routes.
Unlike the limited surface area available for drug absorp-
tion (approximately 180 cm2) in the nasal cavity, the lung
offers a large surface area for drug absorption (approxi-
mately 75 m2) [1]. In addition, the alveolar epithelium is
very thin (approximately 0.1–0.5 mm thick) [2], thereby
permitting rapid drug absorption. The alveoli can be effec-
tively targeted for drug absorption by delivering the drug
as an aerosol, with mass median aerodynamic diameter
(MMAD) less than 5 mm. Also, the first-pass metabolism of
the gastrointestinal tract is avoided. Although metabolic
enzymes can be found in the lungs, the metabolic activi-
ties and pathways may be different from those observed in
the gastrointestinal tract [3], which makes pulmonary
administration of many peptides and proteins very promis-
ing. In addition to the challenges of dosage form, those
posed by the delivery device should also be considered.
In the present review, we present information regarding
recent developments in pulmonary drug administration of
peptides and proteins, with emphasis on pulmonary deliv-
ery of insulin. The biophysical basis of pulmonary adminis-
tration, as well as the barrier properties of the lungs, are
Figure 1
Clinical and potential routes of administration for therapeutic peptides and proteins. Note that small peptides may be absorbed in limited amounts
without absorption enhancers (AE) and/or enzyme inhibitors (EI) via some routes (eg nasal). EP, electroporation/iontophoresis (specific for dermal
delivery); RT, respiratory tract.Respiratory Research    Vol 2 No 4 Agu et al
reviewed in detail. The devices that are available for
general drug administration to the lungs are discussed,
and a comparative treatise of the pulmonary route and
other routes for administration of biopharmaceutical
agents is provided. Finally, both recent clinical and toxo-
logical findings are discussed.
Biophysical basis for pulmonary drug
administration
The anatomical organization of the respiratory tract (charac-
terized by extensive bifurcation) and aerosol characteristics
of drug molecules (especially particle size) generally deter-
mine the reproducibility of pulmonary drug administration.
The respiratory tract comprises the conducting and respi-
ratory regions. The conducting region essentially consists
of nasal cavity, nasopharynx, bronchi and bronchioles.
Airways distal to the bronchioles and the alveoli constitute
the respiratory region, where rapid solute exchange takes
place. According to Wiebel’s tracheobronchial classifica-
tion [4], the conducting airways comprise the first 16 gen-
erations, and generations 17–23 include the respiratory
bronchioles, the alveolar ducts and the alveolar sacs.
The most important parameter that defines the site of
deposition of aerosol drugs, including proteins and pep-
tides, within the respiratory tract is the particle characteris-
tics of the aerosol. The nature of the aerosol droplets is
dependent on its MMAD, which is a function of particle
size, shape and density. Particle charge and air velocities
within the airways are also important attributes. Strict
control of MMAD of the particles ensures reproducibility of
aerosol deposition and retention within desired regions of
the respiratory tract. Good distribution throughout the lung
requires particles with an aerodynamic diameter between
1 and 5 mm, and thus most inhaled products are formu-
lated with a high proportion of drug in this size range [5].
In order to target the alveolar region specifically, the
aerosol droplet diameter should not be more than 3 mm.
Particles with diameters that are greater than 6 mm are
deposited in the oropharynx, whereas smaller particles
(<1 mm) are exhaled during normal tidal breathing.
Dosage forms and delivery devices
Optimal management of most diseases, including diabetes,
requires accurate dosing of the therapeutic compound. Pul-
monary drug administration imposes stringent requirements
on the delivery device; this is because the particle size of
the powder or droplet greatly influences the delivery site,
and thus the degree of drug absorption from the lungs.
The devices that are currently available for pulmonary drug
administration were mostly developed to achieve local
effects of the drug in the conducting airways, such as in
asthma. These devices include nebulizers, metered-dose
inhalers (MDIs) and dry-powder inhalers (DPIs). With
some modification, most of these devices can be used for
pulmonary peptide and protein administration.
Use of nebulizers to administer biopharmaceutical agents
has many important limitations. Such drugs are often very
unstable in aqueous solutions, and are easily hydrolyzed.
In addition, the process of nebulization exerts high shear
stress on the compounds, which can lead to protein
denaturation. This is a particular problem because 99% of
the droplets generated are recycled back into the reservoir
to be nebulized during the next dosing [6]. Furthermore,
the droplets produced by nebulizers are rather heteroge-
neous, which results in very poor drug delivery to the
lower respiratory tract.
MDIs utilize propellants (chlorofluorocarbons and, increas-
ingly, hydrofluoroalkanes) to atomize the drug solution; this
results in a more uniform spray than that achieved with
nebulizers. However, proteins and peptides are susceptible
to denaturation when they come into contact with these
propellants or with the large air–liquid interfaces that are
constantly being generated during aerosolization [3].
A promising alternative to MDIs and nebulizers is the DPI,
in which the biopharmaceutical formulation can be deliv-
ered in dry form. Like MDIs, most DPIs that are currently
approved are made for pulmonary drug administration of
locally acting drugs for the management of asthma and
chronic obstructive pulmonary diseases, such as anti-
asthmatic agents. Examples of such devices include the
Turbohaler (AstraZeneca, Wilmington, DE, USA), Diskhaler
(GlaxoSmithKline, Research Triangle Park, NC, USA),
Diskus (known as the Accuhaler in some countries, for
example the UK; GlaxoSmithKline), Rotahaler (Glaxo-
SmithKline) and Aerolizer (Novartis Pharma, Basel, Switzer-
land), among others. These devices differ not only in their
forms of particle generation and delivery, but also with
regard to design differences such as discrete or reservoir
drug containment, the number of doses and the presence
of a dose counter. Compared with discrete types, the per-
formance of reservoir devices is susceptible to environmen-
tal humidity and moisture. Additionally, dose-to-dose
variations are greater. Furthermore, dose emission for
some can be dependent on inhalation flow rates [7,8].
Drug delivery to the lower respiratory tract from these
DPIs depends strongly on inspiratory air velocity. Conse-
quently, delivery efficiency in children, elderly persons or
adults with certain disease conditions will not always
result in reproducible pharmacokinetics and pharmcody-
namic responses with some devices. An innovative solu-
tion to this problem is offered by the AKITA system
(InAmed GmbH, Gauting, Germany). This is a fully elec-
tronically controlled device that makes use of vital patient
parameters, such as inhalation flow rate, inhaled volume
and inhalation duration, among others, to control the exactdose of the drug administered to the patient. This device
is particularly suited for drugs that are very expensive and
drugs for which accurate dosing is critical, such as insulin,
as well as for research use.
In order to deliver amounts of biopharmaceutical agents
that are greater than those of steroids and other bron-
chodilators that are used in asthma therapy, newer
devices have been developed. Inhale Therapeutics (San
Carlos, CA, USA) and Aradigm Corporation (Hayward,
CA, USA) have developed devices that are currently
undergoing clinical trials, whereas a delivery device devel-
oped by Dura Pharmaceuticals (San Diego, CA, USA) is
still at a preclinical trial stage. The Inhale Therapeutics
device (Inhance) mechanically compresses a fixed volume
of air in order to aerosolize a premetered and sealed dose
of the drug into a chamber. The patient inhales the drug
within 10 s, during a slow and deep breath. This simple
inhalation technique eliminates the complex motor co-ordi-
nation that is often required with MDIs, DPIs and nebuliz-
ers. The major limitation of this device is its large size. The
device from Dura Pharmaceuticals (Spiros motorized blis-
terdisk) relies on a battery-powered motor/impeller, which
is actuated by the patient’s breath to aerosolize a preme-
tered dose of drug in the chamber. The patient inhales
deeply through a mouthpiece that turns on the motor. As
with the Inhance device, patient motor co-ordination is not
required. The AERx delivery system (Aradigm Corporation)
converts large molecules (eg proteins and peptides) into
fine-particle aerosols at the time of use. The device has
unique features, such as computer-controlled processes
and an electronic compliance monitoring system.
Because all of the devices that are currently available have
some shortcomings, it is pertinent to present some of the
features of an ideal pulmonary delivery device. This device
should be portable, discreet and easy to use with minimal
patient education. It should be rechargeable, hygienic,
incorporate a dose counter, be moisture proof and envi-
ronmentally friendly. It should also emit a consistent dose
to the lungs, and be unaffected by the inhalation rate of
the patient.
Barriers to pulmonary absorption of peptides
and proteins
Despite the efficiency of modern pulmonary delivery
devices and advanced dosage form designs, certain barri-
ers still compromise the absorption of peptides and pro-
teins by the lung. Niven [9] identified respiratory mucus,
mucociliary clearance, alveolar lining layer, alveolar epithe-
lium, basement membrane, pulmonary enzymes,
macrophages and other cells as barriers to pulmonary
absorption of biotherapeutic agents. Although the alveolar
epithelium and capillary endothelium have high permeabil-
ity to water, many gases and lipophilic substances, the
permeation of many hydrophilic substances of large mole-
cular size and of ionic species is limited [10]. The molecu-
lar weight cutoff of tight junctions for alveolar type I cells is
0.6 nm. Endothelial junctions allow passage of larger mol-
ecules (4–6 nm).
On reaching the alveoli most peptides and proteins are
either degraded by proteases or removed by alveolar
macrophages. The pulmonary macrophages have also
been shown to secrete or release short-lived peroxidases,
inflammatory and immunomodulatory mediators (including
granulocyte colony-stimulating factor, interleukins,
leukotrienes and proteases), and other molecules as part
of a host defence mechanism. These molecules are able
to degrade peptides and proteins [9].
The mucus (1–10 mm thick) that lines the pulmonary epithe-
lium and the surfactant that lines the alveoli (0.1–0.2 mm
thick) constitute physical barriers to pulmonary absorption
of peptides and proteins. They have high concentrations of
protease inhibitors, and presumably protect peptides and
proteins from degradation. Nonetheless, this protection
appears to be an exception rather than the rule, because
membrane-associated (epithelial and endothelial) and intra-
cellular (macrophages, lymphocytes, neutrophils and mast
cells) proteases and peptidases readily degrade adminis-
tered peptides and proteins [11–14].
Delivery of metabolic hormones
Pulmonary delivery of metabolic hormones, including insulin,
calcitonin, growth hormones, somatostatin, TSH and FSH,
to humans and experimental animals has been reported,
with insulin being the most widely investigated [15–52].
Insulin
Animal studies
In 1971, Wigley et al [15] used animals to investigate pul-
monary insulin absorption, which paved the way for subse-
quent animal studies. Later, studies focused on improving
the reproducibility of the pharmacokinetic and pharmaco-
dynamic profiles of insulin administered via the lung.
Colthorpe et al [16] showed that the penetration index
(peripheral/central deposition) for aerosolized insulin for-
mulation (1.52) was much greater than that for instilled
insulin (0.32) in rabbits. The bioavailable fraction for
aerosolized insulin was more than 20-fold greater than
that for instilled insulin (57.2% versus 2.6%), although the
absorption rate constants were statistically equivalent.
Mucociliary clearance of instilled insulin was probably
responsible for the lower bioavailability with this method of
administration, thus making aerosolization the preferred
mode of delivery of insulin.
In a related study in rats, Okumura et al [17] showed that
the relative bioavailability of insulin solutions was pH
dependent and not higher than 42% (relative to subcuta-
neous administration), whereas the relative bioavailability
Available online http://respiratory-research.com/content/2/4/198
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hof aerosolized insulin was similar to that of subcutaneous
administration. In contrast, Sakr [18] reported the relative
bioavailability of aerosolized insulin in rabbits to be 50%
that of subcutaneous injection. The lower bioavailability
after insulin delivery as aerosol reported by Sakr was
related to insulin retention in the mini-mist nebulizer.
In another study, Jendle et al [19] studied the effect of pul-
monary-delivered insulin in anaesthetized and mechani-
cally ventilated pigs. The nebulized insulin effectively
reduced the mean blood glucose level by 39%. The data
from this study imply that intrapulmonary administration of
insulin in anesthetized and mechanically ventilated animals
results in clinically relevant serum insulin levels.
Independent pilot-scale human studies
Published independent human studies of the efficacy of
pulmonary-delivered insulin involved either nondiabetic vol-
unteers, or patients with type 1 or type 2 diabetes mellitus.
In 1925 Gansslen [20] conducted the first study of the effi-
cacy of insulin after pulmonary administration in humans.
According to that study, inhalation of 30–50 einheiten
insulin (crude animal pancreas extract) reduced blood
glucose level by 26% within 2.5 h. Following this success,
many other small-scale studies were conducted later in the
century. Wigley et al [15] provided direct evidence of
absorption of insulin following aerosol inhalation, and of its
efficacy in inducing hypoglycaemia in one nondiabetic and
three diabetic persons. A correlation was identified
between hypoglycaemia and plasma immunoreactive
insulin. Based on comparisons of plasma immunoreactive
insulin, only 10% of the aerosolized insulin was recovered.
Jendle and Karlberg [21] later showed that the administra-
tion of nebulized insulin can induce a significant hypogly-
caemia and cause a clinically relevant increase in insulin
serum concentration, thus making this route feasible as an
alternative to parenteral injections.
In another study, Laube et al [22] demonstrated the effi-
ciency of optimized deposition of aerosolized insulin in nor-
malizing plasma glucose levels in fasting individuals. That
study indicated that insulin delivered by inhalation and
deposited predominantly within the lung is well tolerated,
and can effectively normalize glucose levels in patients with
type 2 diabetes mellitus. The feasibility of the lung as an
alternative route for insulin administration was further high-
lighted by Laube et al [23] in patients with type 2 diabetes
mellitus. The data from this study showed that, once
plasma glucose levels are normalized, postprandial glucose
levels may be maintained below diabetic level by delivering
insulin into the lung 5 min before the ingestion of a meal.
Although the variability in the metabolic effect of inhaled
insulin is of major importance to diabetic patients, only few
studies have addressed this issue. In a study in seven
patients with type 2 diabetes mellitus, Laube et al [24]
showed that the efficacy of inhaled insulin, as observed in
animal studies [16], is dependent on the region of deposi-
tion in the respiratory tract when compared with subcuta-
neous injection. Thus, deposition outside the alveolar
region results in less reproducible bioavailable fraction in
comparison to subcutaneous injections. Those investiga-
tors found that the ratios of insulin deposition in the larger
central airways versus that in the peripheral airways
(expressed as the inner:outer ratio and lung apex:basal
ratio) were related to glucose responses after inhalation of
insulin. Linear regression analysis identified that the
maximum percentage decrease in glucose after insulin
administration was correlated with lung apex:basal ratio,
whereas no such correlation was found with inner:outer
ratio. This means that increasing the distribution of insulin
aerosol to the alveolar region of the lung enhances the
glucose response in patients with type 2 diabetes mellitus
in the fasting state.
In an attempt to reduce the variability of inhaled insulin,
Pfützner  et al [25] formulated insulin using technos-
pheres. The variability in metabolic effect of technos-
phere–insulin (TI) formulation in 12 type 2 diabetic
patients, in a randomized, four-way, crossover, glucose
clamp study, suggested that TI may be superior to recom-
binant insulin for prandial insulin supplementation in
type 2 diabetic patients; TI showed a more rapid onset
and shorter duration of action. Also lower intrasubject
variability was seen with TI. Similar results were reported
Rave et al [26] using this dosage formulation.
In order to identify possible pharmacokinetic and pharmaco-
dynamic differences between children and adults, Elliott et
al [27] investigated the pulmonary absorption of insulin in
children. To improve the amount of insulin delivered and its
reproducibility, those investigators used a Hudson patient-
activated nebulizer. This device did not eliminate the variabil-
ity associated with pulmonary insulin delivery. Within
patients, the rise in free plasma insulin concentrations
(mU/ml) for a given nebulized dose (0.37–0.49 U dose/day
per kg body weight) was variable, indicating either differ-
ences in the efficiency of deposition and absorption from
time to time, or that some other biological variables (eg vari-
able antibody binding or insulin removal route) were active.
Despite the fact that only a fraction of inhaled insulin is
actually absorbed, independent pilot-scale studies
suggest that the degree of absorption is reproducible.
This is an indication that inhaled insulin is a potential sub-
stitute for subcutaneous injections, especially for patients
with erratic subcutaneous insulin absorption.
Clinical trials
Innovations in powder processing, protein and small-mole-
cule formulations, and aerosol delivery systems have made
clinical trials of aerosol dosage forms of insulin possible.
Respiratory Research    Vol 2 No 4 Agu et alThe major products that are in clinical trial stage are
inhaled insulin (Inhale Therapeutics) and the AERx insulin
delivery system (Aradigm Corporation). The results of
phase 2 clinical studies with these products have been
reported (Table 1).
In 16 patients with type 2 diabetes, Gelfand et al [28]
demonstrated the reproducibility of rapid-acting insulin in
therapeutic amounts of 1–2 inhalations per dose, which
resulted in similar efficacy and safety to that of subcuta-
neous insulin. The insulin was delivered from blister packs
containing either 3 or 9 U insulin per dose using an Inhale
Therapeutics proprietary delivery system. Using the same
delivery device, 3-month, multicenter trials in 121 diabetic
patients (70 type 1 and 51 type 2) [29,30] indicated com-
parable glycaemic control in both groups, and the number
of hypoglycaemic events was similar. These studies also
indicated that patients were satisfied and preferred
inhaled insulin over subcutaneous injections. Capparelli et
al [31] also reported improved patient satisfaction with
inhaled insulin. Preference of inhaled insulin over subcuta-
neous injections was based on ease of use, comfort and
convenience. This observation is important because
improved satisfaction may, in clinical practice, increase
willingness of patients to initiate and comply with insulin
therapy, and hence achieve better glycaemic control. In
another study, Gerber et al [32] demonstrated that patient
preference of inhaled insulin over subcutaneous adminis-
tration did not change with time (1 year), and that the gly-
caemic control was also stable over that period. In another
extended clinical trial (2 years), Cefalu et al [33] empha-
sized the fact that the efficacy of inhaled insulin identified in
short-term clinical trials can be sustained in the long term.
Farr et al [34] used the AERx delivery system for delivery of
insulin in 11 healthy volunteers. These investigators showed
that inhaled insulin, administered as solution (U250 insulin
or U500 insulin), had a faster onset of metabolic effect than
did subcutaneous injection. It was concluded that the deliv-
ery of inhaled insulin to the vast surface area of the lung
could counteract the concentration-dependent absorption
that has been reported after subcutaneous injection. Similar
results were obtained in a related study using the AERx
delivery device [35]. In addition, a clear dose–response was
observed, and the system efficiency of AERx diabetic man-
agement system was approximately 13% that of subcuta-
neous treatment. The AERx delivery system reduced the
dose-to-dose variability in the pharmacokinetic and pharma-
codynamic response to inhaled insulin. Another study [36]
emphasized the reproducibility and safety of inhaled insulin
using the device. Administration of regular insulin with this
device resulted in a reproducible pharmacodynamic effect,
similar to subcutaneous injections, and intrasubject variabil-
ity did not differ significantly from that seen with sub-
cutaneous administration. Reproducibility using this system
was also reported by Brunner et al [37].
It has been proposed that inhaled insulin may serve as
adjunctive therapy to oral therapy in type 2 diabetic patients
in whom oral agents are not effective. In a 3-month, multi-
center, phase 2 trial that involved 69 patients in nine sites,
Weiss et al [38] demonstrated this possibility. That study
showed that, in patients with type 2 diabetes who were not
benefiting from oral agents, a no-injection regimen with
adjunctive inhaled insulin therapy markedly improved gly-
caemic control, with low risk of hypoglycaemia.
Similar pharmacokinetic and pharmacodynamic profiles
have been reported for subcutaneous and inhaled insulin,
but the latter required as high as 15 times the subcuta-
neous dose (1.8 U/kg body weight for inhaled administra-
tion versus 0.12 U/kg body weight for subcutaneous
administration) [37]. Therefore, much formulation and
delivery refinement is necessary before inhalational deliv-
ery of insulin can replace subcutaneous administration.
Calcitonin
Very few attempts have been made to deliver calcitonin
through the lung. Patton et al [39] reported an absolute
bioavailability of approximately 17% for both human and
salmon calcitonin after intratracheal instillation using
catethers in rats. In another study, Komada et al [40]
reported an absolute bioavailability of approximately 12%
when administered as powder to rats and humans. The
difference in bioavailability reported by Patton et al [39]
and Komada et al [40] could be due to the different formu-
lations used (solution versus powder).
Growth hormones
In rats, Folkesson et al [41] demonstrated the passage of
human growth factor (hGH) across the lung to the blood
following administration by instillation. The absorption was
sex-specific, with female rats showing higher bioavailability
than male rats. Colthorpe et al [42], in another study, com-
pared the pharmacokinetics of pulmonary administered
hGH in the form of aerosol (MMAD <5.5 mm) and instillate
in rats. The bioavailable fraction for aerosolized hGH
(45%) was greater than that for instilled hGH (16%). As
suggested for insulin solutions [16], lower bioavailability
for instillate was due to mucociliary clearance.
Using a different approach, Smith et al [53] showed that
pulmonary administration via endotracheal tube of a hexa-
peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, SK&F 110679),
which elicits growth hormone release in animals and
humans, caused dose-related increase in plasma growth
hormone concentrations. In dogs, the bioavailability was
approximately 45% that of intravenous administration.
Thyroid-stimulating hormone, follicle-stimulating
hormone, parathyroid hormone and somatostatin
Pulmonary delivery of parathyroid hormone (PTH) 1–84 and
1–34, TSH, FSH and somatostatin have been investigated
Available online http://respiratory-research.com/content/2/4/198
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Table 1
Summary of clinical and related trials of inhaled insulin
Subjects 
Dosage forms/ (diabetics or 
Insulin doses delivery devices volunteers) Pharmacokinetic profiles and therapeutic outcome Reference
1–2 inhalations per dose Inhaled insulin 70 (type 1) HbA1c (%): 8.51 (INH), 8.53 (SC) [29]
Pulmonary functions: no changes
Acceptance/preference of INH: ³80%.
1–2 inhalations per dose Inhaled insulin 51 (type 1) HbA1c (%): 8.7 (INH), 7.8 (SC) [30]
Pulmonary functions: no changes
Acceptance/preference of INH: 92%
250 U and 500 U AERx DMS 11 (volunteers) Tmax (min): 7 and 16 for INH 250 and 500 U, respectively [34]
Cmax (mU/ml): 29.7 and 23.8 for INH 250 and 500 U, 
respectively
tGmax (min): 66 and 76 for INH 250 and 500 U, respectively
4–6 inhalations per dose Inhaled insulin 16 (type 2) Baseline glucose change: 100 to 53 mg/dl (INH);  [28]
100 to 57 mg/dl (SC)
Pulmonary functions: no change
Reproducibility: INH similar to SC
1–2 inhalations per dose AERx DMS 20 (type 1) Glucose change from baseline (mg/dl): 82 (60 min),  [36]
79 (120 min) and –11 (300 min) for AERx DMS; 
89 (60 min), 82 (120 min) and –25 (300 min) for SC
Deleterious effect: none
1–2 inhalations per dose Inhaled insulin 69 (type 2) Baseline HbA1c (%) before therapy: 9.92 (oral agent  [38]
alone); 9.78 (oral agent + INH)
Change in HbA1c (%) after 2 weeks: –0.13 (oral agent alone); 
2.28 (oral agent + INH)
100 U TI MedTone inhaler (TI) 12 (type 2) GIRmax (mg/kg per min): 5.8 (INH), 2.2 (SC) [25]
(PDC) GIRtmax (min) = 55 (INH), 276 (SC)
USA Early tGIR50% (min): 17 (INH), 122 (SC)
Late tGIR50% (min): 128 (INH), 335 (SC)
Not mentioned Inhaled insulin 70 (type 1) Preference of INH over SC: 81% [32]
Switch from SC to INH: 79%
Continuance of SC: 21%
Satisfaction: 38% (INH), 14% (SC)
Convenience/ease of use: 46% (INH), 12% (SC)
Not mentioned Inhaled insulin Number not stated  HbA1c (%): 8.9 (baseline), 8.0 (after 3 months), 8.1 (after  [33]
(type 1 and type 2) 12 months), 8.0 (after 18 months), 8.0 (after 24 months)
FEV1 (l): 3.2 (baseline), 3.1 (after 12 months), 3.1 (after 
18 months), 3.2 (after 24 months)
DLCO (ml/min per mmHg): 25.6 (baseline), 24.7 (after 
12 months), 24.7 (after 18 months), 24.4 (after 24 months)
Not mentioned Inhaled insulin 56 (type 2) Mean improvement in patient satisfaction (%): 38 (INH),  [31]
14 (SC)
INH preference to SC based on: ease of use, comfort 
and convenience
0.3–1.8 U/kg AERx DMS 18 (type1) Tmax (min): for INH 49, 48, 62 and 65 at doses 0.3, 0.6,  [37]
1.2 and 1.8 U/kg, respectively; for SC 119 at dose 0.12 U/kg
GIRmax (mg/kg per min): for INH 1.6, 2.5, 4.7 and 6.5 at 
doses 0.3, 0.6, 1.2 and 1.8 U/kg, respectively; for SC 3.2 
at dose 0.12 U/kg
tGIRmax (min): for INH 94, 136, 157 and 218 at doses 0.3, 
0.6, 1.2 and 1.8 U/kg, respectively; for SC 189 at dose 0.12 U/kg
25–100 U MedTone inhaler (TI) 12 (volunteers) GIRmax (mg/kg per min): concentration dependent [26]
(PDC) GIRtmax (min): 47, 52, 56 for TI 25, 50 and 100 U, respectively; 
192 for SC
Tmax (min): 12, 18, and 21 for TI 25, 50 and 100 U, respectively; 
for SC 153
Bioavailability (relative to SC for 3 h): 46, 42 and 28% for TI 25, 
50 and 100 U, respectively
Cmax, maximum insulin concentration; DLCO, diffusion capacity; DMS, diabetic management system; FEV1, forced expiratory volume in 1 s; GIRmax,
maximum glucose infusion rate; GIRtmax, time to maximum glucose infusion rate; HbA1c, glycated haemoglobin (glycaemic control index); INH,
inhaled insulin; PDC, Pharmaceutical Discovery Corporation (Elmsford, NY, USA); SC, subcutaneous; tGIR50%, time to late half maximum glucose
infusion rate; tGmax, time to maximum glycemic effect; Tmax, time to maximum concentration of insulin.Available online http://respiratory-research.com/content/2/4/198
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[37,38]. Bioavailabilities following pulmonary administra-
tion by instillation using silicone tubing or catheters
were as follows: PTH 84, >23%; PTH 34, approxi-
mately 40%; and somatostatin, <1%. The bioavailabili-
ties of TSH and FSH delivered in solution of neutral pH
were similar (2.5 and 2.3%, respectively). The bioavail-
abilities of TSH and FSH in alkaline conditions were two
to 30 times greater than those in neutral pH conditions.
On the other hand, the bioavailabilities of TSH and FSH
when given intratracheally as dry powder were 1.6 and
0.6%, respectively.
Delivery of luteinizing hormone-releasing
hormone agonist/antagonists
The pulmonary delivery of leuprolide (luteinizing hormone-
releasing hormone agonist), detirelix and cetrorelix
(luteinizing hormone-releasing hormone antagonists) by
intratracheal intubation or aerosol administration (MMAD
2.6 mm) has been reported.
Adjei and coworkers [54–56] clearly showed that
leuprolide acetate attains high plasma concentrations
after pulmonary aerosol delivery or instillation. A corre-
sponding decrease in plasma gonadotrophin, with
sequential increases in plasma leuprolide concentra-
tions, was observed in these studies. In one of the
studies [55], the investigators reported decreases in
bioavailability when solution aerosols were administered.
Subsequently they showed [56] that using a suspension
aerosol instead of a cosolvent solution aerosol formula-
tion of leuprolide resulted in a dose-related increase in
plasma concentration. According to the authors,
decreases in lung bioavailability were related to mild
microscopic and inflammatory reactions of the lung
tissue caused by the cosolvent (alcohol), which affected
absorption when the cosolvent was used.
Pulmonary administration of detirelix has been investi-
gated in anaesthetized dogs [57] and awake sheep [58].
In dogs the relative bioavailability was 29% following
aerosol administration, and a similar profile was seen with
instillation. In unanaesthethized sheep the average
bioavailability following pulmonary administration as instil-
late or aerosol was approximately 10%. No significant
changes in pharmacokinetic or systemic uptake of detire-
lix were observed during the 5-month period of repeated
pulmonary administration.
Lizio et al [59] investigated the bioavailability of cetrore-
lix after pulmonary instillation in rats. When compared
with intravenous administration, the absolute bioavail-
abilty of intratracheal cetrorelix was more than 70%.
According to that study, pulmonary administration of
0.5–2.5 mg/kg body weight cetrorelix decreased
plasma concentrations of testosterone to subnormal
levels (£1 ng/ml) within 72 h.
Delivery of cardiovascular peptides:
vasopressin analogue
Folksson and coworkers [60,61] showed that high plasma
concentrations of an analogue of vasopressin (1-deamino-
8-D-arginine vasopressin [dDAVP]) could be attained fol-
lowing administration via the lung by instillation. These
investigators found that the passage of dDAVP aerosol
and instillate via the rat lung was age dependent, and was
significantly increased in inflammatory conditions [60].
They also demonstrated pulmonary absorption of dDAVP
in pigs [61]. As in previous studies, a significant decrease
in total passage of dDAVP was observed with age:
74.6 ± 9.4% in the newborn, 44.1 ± 13.3% in 2 day old
pigs and 23.6 ± 7.1% in 70 day old pigs. These data indi-
cate that proteins and peptides may traverse the lung
epithelium via different routes that are differently affected
during postnatal development.
Delivery to induce systemic response
Recent studies have shown that a systemic response may
be achieved following pulmonary administration of certain
macromolecules. This has been demonstrated for
immunoglobulins, CsA, r-huG-CSF, pancreatic islet auto-
antigen insulin and interferons.
Immunoglobulins
Delivery of specific antibodies or immunoglobulin con-
structs to the respiratory tract may be useful for prophy-
laxis or active treatment of local or systemic disorders.
Folkesson et al [60] showed the possibility of systemic
delivery of immunoglobulins via the lung. In their studies,
the passage of bovine immunoglobulin was extremely
slow, except in inflammation, with a transferred amount of
1.5 ± 0.3% after 16 h in young rats. For older rats, similar
passage time curves were obtained, but the amount of
bovine immunoglobulin transferred was lower. Using an
entirely different approach, Bot et al [62] investigated pul-
monary delivery of human immunoglobulin (MMAD
4.6 mm) using microparticles (Pulmospheres; Alliance
Pharmaceutical Corporation, San Diego, CA, USA) as a
platform for delivery. Instillation of nonaqueous human
immunoglobulin formulated in Pulmospheres to the respi-
ratory tract of BALB/c mice resulted in systemic biodistrib-
ution. The formulation triggered enhanced local and
systemic immune responses against xenotypic epitopes,
and was associated with receptor-mediated loading of
alveolar macrophages. Thus, local and systemic delivery of
immunoglobulins via the respiratory mucosa may be used
to trigger or modulate immune responses.
Pancreatic islet autoantigen insulin
Delivery of aerosols that contain soluble immunologically
active self-antigens such as collagen and myelin-basic
proteins to the respiratory tract has been suggested as
therapy for autoimmune diseases such as rheumatoid
arthritis and multiple sclerosis, as a result of induction ofsystemic tolerance. Such an approach may be extended to
diabetes mellitus. In a study of mucosal tolerance in
autoimmune diabetes using the nonobese diabetic mouse
model, Hänninen and Harrison [63] reported that treatment
of prediabetic mice with the pancreatic islet autoantigen
insulin by aerosol (MMAD <5.8mm) inhalation reduced the
incidence of diabetes. The reduction was associated with
induction of CD8+ (aa) gd T cells, small numbers of which
prevent adoptive transfer of diabetes. Regulatory gd T cells
secrete interleukin-10 in pancreatic lymph nodes, which
could account for the antidiabetic and bystander suppres-
sor effect of nasorespiratory insulin [64].
Interferons 
High plasma concentrations of recombinant-methionyl inter-
feron consensus (rCon-IFN) and interferon-a have been
attained following pulmonary administration to animals.
Patton et al [39] found the absolute bioavailability of inter-
feron-a in rats to be greater than 56% following intratra-
cheal instillation. Altrock et al [65] reported that, in
hamsters infected with encephalomyelocarditis virus, sig-
nificant protection was conferred following intratracheal
instillation of rCon-IFN (5 mg/kg body weight). On the
other hand, Niven et al [66] compared the pharmacokinet-
ics and bioavailability of rCon-IFN and a modified lactose-
conjugated consensus interferon in rat and hamster. After
aerosol administration to rat, the estimated bioavailability
of both compounds approached 70%, and rCon-IFN
(5 mg/kg body weight) was effective in reducing the inci-
dence of paralysis in the hamsters. These results demon-
strate the feasibility of treating systemic viral infections
with interferon administered directly to the lung.
Recombinant-methionyl human granulocyte 
colony-stimulating factor
Systemic delivery of r-huG-CSF can readily induce an
increase in circulating levels of natural granulocyte colony-
stimulating factor to approximately three to five times greater
than baseline. Niven et al [67] showed that r-huG-CSF
induced systemic response after delivery by aerosol in ham-
sters. The absorption from the lung was rapid, with a con-
comitant increase in white blood cells to four times baseline.
The bioavailability was 45.9% of the administered dose, and
62.0% of the dose reached the lung lobes. In a study that
compared pulmonary administration of r-huG-CSF powder
with solution [68] a normal systemic response was obtained,
indicating that r-huG-CSF retains its activity in the solid state
after formulation. Dissolution and absorption of r-huG-CSF
from powders were not rate limiting, because the plasma
concentration versus time profiles peaked at similar times in
both powder and solution administration.
Cyclosporin A
CsA is widely used in organ transplantation and abnormal
immune reactions. After instillation of CsA with micelles-
forming surfactant (Cremophor EL) in adult and young
rats, Taljanski et al [69] showed that the plasma levels
peaked at 5 min, with bioavailability of 77.5 ± 7.2% and
66.3 ± 4.5%, respectively. The bioavailability of aerosolized
CsA was 80.1 ± 4.1% in adults. The investigators con-
cluded that CsA was absorbed by the lungs into the sys-
temic circulation in rats in high concentrations,
independent of age and type of delivery system. This may
be of clinical relevance to treatment of chronic rejection.
Delivery with absorption enhancers and
enzyme inhibitors
Physical barriers and enzymatic degradation, among other
factors, limit pulmonary absorption of peptides and pro-
teins. Part of the strategy to improve pulmonary absorption
of macromolecules via the lung includes co-administration
with absorption enhancers and enzyme inhibitors. This
approach has been shown to improve the bioavailabilities
and pharmacodynamic response of biotherapeutic agents,
including insulin, calcitonin and others.
Shao et al [43] reported the effectiveness of cyclodextrins
as pulmonary absorption promoters. The relative effective-
ness of cyclodextrins in enhancing pulmonary insulin
absorption, as measured by pharmacodynamics, and rela-
tive efficiency is according to the following rank order:
dimethyl-b-cyclodextrin > a-cyclodextrin > b-cyclodextrin >
g-cyclodextrin > hydroxypropyl-b-cyclodextrin. In another
study, Shen et al [44] showed that lanthanide ions are
effective in promoting pulmonary insulin absorption in rats.
The effectiveness of absorption enhancers for pulmonary
insulin delivery was confirmed by Heinemann et al [45], in a
single-centre, open euglycaemic glucose clamp study in
13 healthy male volunteers. Insulin inhaled with bile salt as
an absorption enhancer led to a considerably greater meta-
bolic effect than was seen with inhalation of insulin alone,
although the intra-individual variabilities were comparable.
Furthermore, the potential usefulness of enzyme inhibition
to improve absorption of biotherapeutic agents via the
lung has been demonstrated [12–14]. In addition to
insulin, the pulmonary absorption of salmon calcitonin [46]
and (ASU1,7)-Eel calcitonin [47,48] have been shown to
be more efficient with absorption enhancers (oleic acid,
polyoxyethylene oleyl ether, sodium glycocholate) and
enzyme inhibitors (bacitracin, bestatin, nafanostat mesi-
late, soybean trypsin inhibitor, chymostatin, potato car-
boxypeptidase inhibitor, phosphoramidon).
Delivery with microparticles
The human lung has efficient mechanisms to remove
deposited particles by mucociliary clearance and phago-
cytosis. When peptide and protein drugs are formulated
using microparticles as vehicles, the influence of these
clearance mechanisms may be attenuated, and more effi-
cient absorption and a sustained therapeutic effect may
Respiratory Research    Vol 2 No 4 Agu et albe achieved. Edwards et al [49] showed that inhalation of
large porous insulin particles (formulated with poly[lactic
acid-co-glycolic acid]) resulted in elevated systemic levels
of insulin and suppressed systemic glucose levels for
96 h, whereas small, nonporous insulin particles had this
effect for only 4 h. Similarly, Kawashima et al [50] reported
that the pulmonary delivery of insulin with nebulized
DL-lactide/glycocholide copolymer nanospheres resulted
in prolonged hypoglycaemia (48 h) as compared with the
nebulized aqueous solution (6 h). The observed prolonged
insulin concentrations and hypoglycaemic effect in these
studies was attributed to the sustained release of insulin
from the polymers.
Other studies have shown enhancement of pulmonary
insulin absorption using liposomes as carriers. Liu et al
[51] reported that intratracheal administration of insulin
liposomes (dipalmitoylphosphatidyl choline:cholesterol,
7:2) led to facilitated pulmonary uptake of insulin and
enhanced hypoglycaemic effect. The ability of liposomes
to promote pulmonary insulin absorption depends on the
concentration, charge and acyl chain length of the phos-
pholipid [52]. In another study, Niven et al [70] empha-
sized the use of polyethyleneglycol for systemic delivery of
r-huG-CSF. According to these authors, the pulmonary
absorption of polyethylene glycolated r-huG-CSF in rat
generated a more intense response and extended white
blood cell response, as compared with r-huG-CSF alone.
Safety aspects of pulmonary peptide and
protein delivery
The major concern regarding pulmonary administration of
therapeutic peptides and proteins via the lung is the possi-
bility of immunological reactions, because the body may
recognize these molecules as antigens. A recent review by
Wolff [71] suggested that pulmonary delivery of most ther-
apeutic peptides and proteins is safe, at least after short-
term use. In type 1 and type 2 diabetic patients, Cefalu et
al [33] recently showed that pulmonary insulin administra-
tion over a 2 year period is safe.
Safety in use of absorption enhancers and enzyme
inhibitors is of major concern. Yamamoto et al [48]
showed a correlation between pulmonary absorption of
calcitonin and local toxicity in the presence of absorption
enhancers. The improved pharmacodynamic response
seen with insulin in the presence of bile salt [45] may not
be clinically advantageous, especially for chronic use, as
bile salts erode epithelial surfaces.
Microparticles used to improve systemic delivery of pep-
tides and proteins via the lung may have a detrimental
effect, although the safety of some of them (eg liposomes)
has been demonstrated [72]. Nevertheless, Dokka et al
[73] recently reported that pulmonary administration of
some liposomes may be detrimental, depending on the
charge of the liposome. Reactive oxygen species were
implicated in cationic lipid-mediated toxicity. Polyvalent
cationic liposomes cause a release of reactive oxygen
species, which are responsible for pulmonary toxicity.
When peptides and proteins are coadministered with
absorption enhancers or enzyme inhibitors, or are deliv-
ered using microparticles, the safety of the adjuvant must
be ascertained, both in short-term and long-term use.
Conclusion
Pulmonary drug delivery offers the opportunity for sys-
temic administration of peptides and proteins that are at
present usually administered parenterally. It is expected
that the continued research interest in this route of admin-
istration will lead to more breakthroughs in several areas
of both formulation and device design, and as such the
market and benefits to patients will improve. Pulmonary
drug administration research should be integrated. Those
who are developing formulations with very high drug
absorption should keep in mind the importance of safety
and convenience. This is the only way to ensure, on a
long-term basis, the success of a particular formulation in
a given disease state. Although the current status of pul-
monary administration of insulin is promising, the possible
side effects following chronic use (10–20 years) are yet to
be ascertained.
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